Fan Y, Chen L, Zheng Y, Li A, Lin H, Gao J
Chem Biomed Imaging. 2024; 1(3):192-204.
PMID: 39473694
PMC: 11504611.
DOI: 10.1021/cbmi.3c00024.
Gu X, Minko T
Cancers (Basel). 2024; 16(8).
PMID: 38672671
PMC: 11048786.
DOI: 10.3390/cancers16081589.
Meng Y, Sun J, Zhang G, Yu T, Piao H
Bioengineered. 2022; 13(6):14844-14855.
PMID: 36469646
PMC: 9728467.
DOI: 10.1080/21655979.2022.2096303.
Mahani M, Karimi-Mazidi P, Khakbaz F, Torkzadeh-Mahani M
Mikrochim Acta. 2022; 189(2):69.
PMID: 35066672
DOI: 10.1007/s00604-021-05147-8.
Majumder J, Minko T
Adv Ther (Weinh). 2020; 4(2):2000203.
PMID: 33173809
PMC: 7646027.
DOI: 10.1002/adtp.202000203.
Enhancing the Efficacy of Metal-Free MRI Contrast Agents via Conjugating Nitroxides onto PEGylated Cross-Linked Poly(Carboxylate Ester).
Guo S, Wang X, Dai Y, Dai X, Li Z, Luo Q
Adv Sci (Weinh). 2020; 7(14):2000467.
PMID: 32714757
PMC: 7375229.
DOI: 10.1002/advs.202000467.
Nanodrug Delivery Systems for the Treatment of Ovarian Cancer.
Pantshwa J, Kondiah P, Choonara Y, Marimuthu T, Pillay V
Cancers (Basel). 2020; 12(1).
PMID: 31952210
PMC: 7017423.
DOI: 10.3390/cancers12010213.
Nanoparticle Interactions with the Tumor Microenvironment.
Huai Y, Hossen M, Wilhelm S, Bhattacharya R, Mukherjee P
Bioconjug Chem. 2019; 30(9):2247-2263.
PMID: 31408324
PMC: 6892461.
DOI: 10.1021/acs.bioconjchem.9b00448.
Updated developments on molecular imaging and therapeutic strategies directed against necrosis.
Zhang D, Gao M, Jin Q, Ni Y, Zhang J
Acta Pharm Sin B. 2019; 9(3):455-468.
PMID: 31193829
PMC: 6543088.
DOI: 10.1016/j.apsb.2019.02.002.
Use of Nanoparticles in Tissue Engineering and Regenerative Medicine.
Fathi-Achachelouei M, Knopf-Marques H, da Silva C, Barthes J, Bat E, Tezcaner A
Front Bioeng Biotechnol. 2019; 7:113.
PMID: 31179276
PMC: 6543169.
DOI: 10.3389/fbioe.2019.00113.
Polydopamine/Transferrin Hybrid Nanoparticles for Targeted Cell-Killing.
Hauser D, Estermann M, Milosevic A, Steinmetz L, Vanhecke D, Septiadi D
Nanomaterials (Basel). 2018; 8(12).
PMID: 30562983
PMC: 6315732.
DOI: 10.3390/nano8121065.
Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy.
Yun T, Liu Y, Yi S, Jia Q, Liu Y, Zhou J
Int J Nanomedicine. 2018; 13:6647-6659.
PMID: 30425480
PMC: 6205544.
DOI: 10.2147/IJN.S182206.
Neurotheranostics as personalized medicines.
Kevadiya B, Ottemann B, Thomas M, Mukadam I, Nigam S, McMillan J
Adv Drug Deliv Rev. 2018; 148:252-289.
PMID: 30421721
PMC: 6486471.
DOI: 10.1016/j.addr.2018.10.011.
Gold Nanorods for Light-Based Lung Cancer Theranostics.
Knights O, McLaughlan J
Int J Mol Sci. 2018; 19(11).
PMID: 30366384
PMC: 6274674.
DOI: 10.3390/ijms19113318.
Coating Matters: Review on Colloidal Stability of Nanoparticles with Biocompatible Coatings in Biological Media, Living Cells and Organisms.
Schubert J, Chanana M
Curr Med Chem. 2018; 25(35):4553-4586.
PMID: 29852857
PMC: 7040520.
DOI: 10.2174/0929867325666180601101859.
Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F, Yan J, Ma B, Li S, Shao Y, He P
Biomaterials. 2018; 167:132-142.
PMID: 29571049
PMC: 5889738.
DOI: 10.1016/j.biomaterials.2018.03.025.
Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands.
Cao S, Jiang Y, Levy C, Hughes S, Zhang H, Hladik F
J Biomed Mater Res A. 2017; 106(5):1177-1188.
PMID: 29271128
PMC: 6038932.
DOI: 10.1002/jbm.a.36315.
One-Step Facile Synthesis of Highly Magnetic and Surface Functionalized Iron Oxide Nanorods for Biomarker-Targeted Applications.
Orza A, Wu H, Xu Y, Lu Q, Mao H
ACS Appl Mater Interfaces. 2017; 9(24):20719-20727.
PMID: 28513139
PMC: 8898331.
DOI: 10.1021/acsami.7b02575.
Precision targeted therapy of ovarian cancer.
Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T
J Control Release. 2016; 243:250-268.
PMID: 27746277
PMC: 5191987.
DOI: 10.1016/j.jconrel.2016.10.014.